EUCTR2013-000043-78-NL进行中（未招募）1 期
Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observation - ADMEC-O
niversity of Essen0 个研究点目标入组 190 人开始时间: 2019年7月3日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The patient is willing and able to give written informed consent.
- •2. Central histological confirmation of diagnosis of Merkel cell carcinoma (MCC).
- •3. All MCC manifestations have been completely resected by surgery within 12 weeks before enrolment.
- •4. No currently present metastases (as confirmed by standard imaging studies (e.g. suggested by S2k guidelines).
- •5. No previous systemic therapy for MCC.
- •6. Required values for initial laboratory tests:
- •- WBC = 2000/uL
- •- ANC = 1000/uL
- •- Platelets = 75 x 103/uL
- •- Hemoglobin = 8 g/dL (= 80 g/L)
- •- Creatinine = 2.0 x ULN
- •- AST/ALT = 2.5 x ULN
- •- Total Bilirubin = 2.0 x ULN (except patients with Gilbert’s Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
- •7. ECOG performance status of 0 or 1.
- •8. No active or chronic infection with HIV, Hepatitis B or C.
- •9. Men and women, = 18 years of age.
- •10. Women of childbearing potential (WOCBP) must be using an adequate method of contraception (Pearl-Index < 1) to avoid pregnancy during treatment phase and for additional 5 months after the last dose of nivolumab, in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not post-menopausal. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours before the start of nivolumab.
- •11. Men of fathering potential must be using an adequate method of contraception to avoid conception during treatment phase and for additional 7 months after the last dose of nivolumab) in such a manner that the risk of pregnancy is minimized.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 155
排除标准
- •1. Autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn’s Disease, are excluded from this study, as are patients with a history of symptomatic disease requiring systemic steroids (e.g., rheumatoid arthritis, systemic progressive sclerosis, systemic lupus erythematosus, autoimmune vasculitis); autoimmune motor neuropathy.
- •2. Other serious illnesses, e.g., serious infections requiring i.v. antibiotics.
- •3. The patient is known to be positive for Human Immunodeficiency Virus (HIV) or other chronic infections (HBV, HCV) or has another confirmed or suspected immunosuppressive or immune deficient condition.
- •4. Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of nivolumab hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea.
- •5. Any non-oncology vaccine therapy for up to 1 month before or after any dose of nivolumab.
- •6. A history of prior or current treatment with a T cell potentiating agent (e.g. IL-2, interferon, anti-CTLA-4, anti-CD137, anti-PD1, anti-PD-L1, or anti-OX40 antibody).
- •7. Chronic use of immunosuppressive agents or systemic corticosteroids.
- •8. Women of childbearing potential (WOCBP), defined above in Section 5.1, who:
- •are unwilling or unable to use an acceptable method of contraception to avoid pregnancy during treatment phase and for additional 5 months after the last dose of investigational product
- •have a positive pregnancy test at baseline
- •are pregnant or breastfeeding.
- •9. The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the trial procedures.
- •10. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness.
- •11. Men of reproductive potential unwilling to use an adequate method to avoid pregnancy during treatment phase and for additional 7 months after the last dose of investigational product.
- •12. Use of any investigational or non-registered product (drug or vaccine) other than the study treatment.
研究者
相似试验
尚未招募
2 期
Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observatioNL-OMON50102niversity Hospital Essen30
进行中（未招募）
1 期
Comparison of therapy of Merkel Cell Carcinoma (MCC) with Ipilimumab (Yervoy®) or Nivolumab (Opdivo®) versus observation onlycompletely resected Merkel cell carcinomaMedDRA version: 21.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000043-78-DEniversity of Essen190
已完成
不适用
A prospective randomised trial of adjuvant chemotherapy in node positive early stage carcinoma of the cervixCervix cancerMalignant neoplasm of cervix uteriCancerISRCTN52711596Cancer Research UK (CRUK) (UK)
进行中（未招募）
不适用
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high risk of relapse based on the Pervenio? Lung RS AssayCompletely resected stage I non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864EUCTR2013-001494-24-ESEncore Clinical, Inc1,050
进行中（未招募）
1 期
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high or intermediate risk of relapse based on a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029517Term: Non-small cell lung cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029518Term: Non-small cell lung cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001494-24-FRIFCT1,050